144 related articles for article (PubMed ID: 17639046)
1. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.
Mody M; Dharker N; Bloomston M; Wang PS; Chou FS; Glickman TS; McCaffrey T; Yang Z; Pumfery A; Lee D; Ringel MD; Pinzone JJ
Endocr Relat Cancer; 2007 Jun; 14(2):305-15. PubMed ID: 17639046
[TBL] [Abstract][Full Text] [Related]
2. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth.
Pon CK; Firth SM; Baxter RC
Mol Cell Endocrinol; 2015 Jan; 399():354-61. PubMed ID: 25449421
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
Higashi Y; Holder K; Delafontaine P
J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
[TBL] [Abstract][Full Text] [Related]
5. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
6. Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells.
Talbert DR; Allred CD; Zaytseva YY; Kilgore MW
Breast Cancer Res Treat; 2008 Mar; 108(1):23-33. PubMed ID: 17453334
[TBL] [Abstract][Full Text] [Related]
7. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
8. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
9. EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
Chbicheb S; Yao X; Rodeau JL; Salamone S; Boisbrun M; Thiel G; Spohn D; Grillier-Vuissoz I; Chapleur Y; Flament S; Mazerbourg S
Biochem Pharmacol; 2011 May; 81(9):1087-97. PubMed ID: 21338579
[TBL] [Abstract][Full Text] [Related]
10. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
11. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.
Yi JH; Park SW; Brooks N; Lang BT; Vemuganti R
Brain Res; 2008 Dec; 1244():164-72. PubMed ID: 18948087
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
[TBL] [Abstract][Full Text] [Related]
15. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
Seargent JM; Yates EA; Gill JH
Br J Pharmacol; 2004 Dec; 143(8):933-7. PubMed ID: 15533890
[TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
Pseftogas A; Gonidas C; Mosialos G
Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
18. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
Morgado M; Carson DD
J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
